



PROGRAM BOOK

2023 Annual Scientific Meeting

5 - 8 November

Melbourne Convention and Exhibition Centre



The combined Annual Scientific Meeting of the:



HSANZ
Haematology Society of
Australia and New Zealand



Australian & New Zealand
Society of Blood Transfusion Ltd



THANZ
Thrombosis & Haemostasis society
of Australia and New Zealand

Thank you to our Sponsors

Platinum Sponsors



Gold Sponsors



Silver Sponsors



Lounge Sponsor



Meeting App Sponsor



Welcome Reception Sponsor



Welcome to BLOOD 2023

We are delighted to welcome you to Melbourne for Blood 2023, the combined Annual Scientific Meeting of the Haematology society of Australia and New Zealand (HSANZ), the Australian and New Zealand society of Blood Transfusion (ANZSBT), and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ), together with important contributions from the HSANZ Nurses Group and the Bone Marrow Transplant society of Australia and New Zealand.

We hope you will find the Blood 2023 program educational and stimulating, and we are very grateful to all our speakers for the willingness to share their knowledge and expertise. We would like to pay particular thanks to our international speakers who have travelled a long way to share their experience and unique insights.

We wish to thank our sponsors and exhibitors for their generous support of the Blood 2023 meeting. Please take the time to visit the exhibition stands and interact throughout the breaks.

In true Blood fashion, the social functions will be an important part of the meeting too. Your opportunity to reconnect with old friends and meet new ones at the Welcome Function. Celebrate the arrival of Spring and new beginnings at the Gala Dinner, come dressed in your best garden party attire.

We hope that you enjoy the many educational, social and networking opportunities that occur throughout the Meeting and leave with new knowledge and connections.

On behalf of the Local Organising Committee

Local Organising Committee

HSANZ: Bill Renwick & Meaghan Wall

ANZSBT: Amanda Ormerod

THANZ: Cherry Keragala & James McFadyen

Nurses: Lindsay Scudder



HSANZ
Haematology Society of
Australia and New Zealand



Australian & New Zealand
Society of Blood Transfusion Ltd



THANZ
Thrombosis & Haemostasis society
of Australia and New Zealand

Contents

Meeting Venue	1
Social Program	3
Ancillary Meetings	4
Program Sunday 5 November	5
Program Monday 6 November	9
Program Tuesday 7 November	17
Program Wednesday 8 November	26
International Speakers	28
Orators	29
General Information	30

Registration Desk

The desk is located on the exhibition concourse, opposite door 7 and open at the following time:

Sunday 5 November	0730-1800hrs
Monday 6 November	0730-1800hrs
Tuesday 7 November	0730-1800hrs
Wednesday 8 November	0800-1300hrs


Meeting Managers

Email:	blood@theconferencecompany.com
Telephone:	1800 193 405 (Australian Freephone) +64 9 360 1240 (International)
Postal:	Level 35, International Tower One, 100 Barangaroo Avenue, Sydney, 2000, NSW Or PO Box 90040, Auckland 1142

**THE
CONFERENCE
COMPANY**

Meeting Venue

Ground Level




■ **Exhibition, Posters
& Catering (Door 7)**

■ **Registration Desk
(Concourse)**

■ **Plenary Sessions
(Plenary Room 3)**

A **Parents Rooms
(A)**

Level 2



Speaker Preparation Room
(Meeting Room 215)

Concurrent Sessions (Meeting Rooms
212-213, 216, 217, 218, 219, 220)

Microscope Viewing
(Meeting Room 214)

Gala Dinner
(Melbourne Rooms)

Social Program

Welcome Reception

- Date:** Sunday 5 November, 1800hrs
- Venue:** Melbourne Convention and Exhibition Centre, Exhibition Hall
- Tickets:** Attendance inclusive with full registration fees (entry by wearing your lanyard).
Guest tickets are AU\$90 incl GST per person, available from the registration desk.
- Dress code:** Smart casual

Join us at the end of the Sunday program for an opportunity to mingle with old friends and acquaint yourself with new connections while enjoying some of the best food and wine from the Victoria region.

The Welcome Reception is sponsored by



Gala Dinner and Awards

- Date:** Tuesday 7 November, 1900-late
- Venue:** Melbourne Convention and Exhibition Centre, Level 2, Melbourne Room
- Tickets:** Delegate ticket inclusive with full registration fees.
Guest tickets are AU\$195 incl GST per person, available from the registration desk.
- Dress code:** Step into Spring



Celebrate BLOOD 2023 in your garden party inspired outfit and come ready to dance the night away!



Ancillary Meetings

Saturday 4 November

ANZSBT Council Meeting	0900 - 1200, 1330 - 1430	Room 206	Closed Meeting
Joint Societies Meeting	1230 - 1330	Room 214	Closed Meeting
HSANZ Council Meeting	1330 - 1700	Room 214	Closed Meeting
HSANZ Advanced Trainee Workshop	1030 - 1630	Room 210	Attendance by registration only
THANZ Scientific Workshop	0900 - 1730	Room 220	Attendance by registration only
Transfusion Practitioner Study Day	0930 - 1630	Room 217	Attendance by registration only

Sunday 5 November

BMTSAA AGM	1200 - 1300	Room 211	Open to Members
THANZ Council	1200 - 1300	Hospitality Suite	Closed Meeting
ANZSBT AGM	1200 - 1300	Room 219	Open to Members
Nurses Members Meeting	1200 - 1300	Room 220	Open to Members

Monday 6 November

THANZ AGM	1200 - 1300	Room 219	Open to Members
Myeloma Special Practice Network Meeting	1200 - 1300	Room 220	Open to Members

Tuesday 7 November

HSANZ AGM	1200 - 1300	Room 218	Open to Members
Apheresis Special Practice Network Meeting	1200 - 1300	Room 220	Open to Members

Wednesday 8 November

THANZ Committee Meeting	1300 - 1400	Room 216	Closed
SPDP Workshop	1300 - 1600	Room 217	Attendance by registration only

Meeting Program

Sunday 5 November

At a Glance

0930-1015	Morning Tea Exhibition Hall				
1015-1030	Opening and Welcome to Country Plenary 3				
1030-1200	Combined Opening Plenary Plenary 3			BMTSAA Symposium Meeting Room 211	
1200-1300	Lunch Exhibition Hall				
1200-1300	ANZSBT AGM Meeting Room 219				
1200-1300	Nurses Members Meeting Meeting Room 220				
1300-1400	Barry Firkin Oration: Musings of a Firkin mentee Plenary 3 Prof Shaun Jackson				
1400-1530	HSANZ & ANZTCT Symposium: Cellular therapies Plenary 3	ANZSBT Symposium: Red cells behaving badly! Meeting Room 212 & 213	THANZ Symposium: Platelet formation, function and therapy - novel insights Meeting Room 219 <i>(Kindly sponsored by Swedish Orphan Biovitrum (Sobi))</i>	Nurses Symposium: Familial haematology Meeting Room 220	
1530-1600	Afternoon Tea Exhibition Hall				
1600-1730	HSANZ Symposium: AML Plenary 3 <i>(Kindly sponsored by AbbVie)</i>	ANZSBT Symposium: Implementing change Meeting Room 212 & 213	THANZ Symposium: Emerging technologies in thrombosis and haemostasis Meeting Room 219	Nurses Symposium: Update on new therapies Meeting Room 220	BMTSAA Symposium Meeting Room 211
1730-1930	Welcome Reception Exhibition Hall (Supported by BeiGene)				

Sunday 5 November

0930 - 1015	Morning Tea	Exhibition Hall
1015 - 1200	Opening and Combined Session <i>Chairs: Bill Renwick, Lindsay Scudder, Amanda Ormerod, Chee Wee Tan</i>	Plenary 3
1015	Welcome to Country	
1032	Defining global strategies to improve outcomes in sickle cell disease	Anthea Greenway
1054	Addressing the digital divide: Mitigating health inequities	Linda Watson
1116	Prevention and treatment of anaemia in low income countries	Sant-Rayn Pasricha
1138	Challenges in the management of hemophilia in resource-constrained settings	Pantep Angchaisuksiri
1030-1200	BMTSAA Symposium <i>Chair: Kerrie Clerici</i>	Meeting Room 211
1030	Bench to bedside (impact of COVID - pre and post COVID date assessing fresh vs cryopreserved products)	Michael Swain
1100	Building a CAR-T program at The Alfred Hospital	Joanna Youngson
1130	From bench to bedside - nuances of collection and delivery for the various CAR-T's delivered at PMCC	Janu Davawala
1200 - 1300	Lunch	Exhibition Hall
1200 - 1300	ANZSBT AGM	Meeting Room 219
1200 - 1300	Nurses Members Meeting	Meeting Room 220
1300 - 1400	Barry Firkin Oration <i>Chair: Chee Wee Tan</i>	Plenary 3
1300	Musings of a Firkin mentee	Shaun Jackson
1400 - 1530	HSANZ & ANZTCT Symposium: Cellular therapies <i>Chairs: Ashish Bajel and Shu Min Wong</i>	Plenary 3
1400	Immunotherapy for myeloma	Adam Cohen (supported by Janssen)
1430	Is autograft dead in DLBCL?	Mary Ann Anderson
1500	The role of transplantation in myeloid disorders	David Curtis

...continued overleaf

1400 - 1530	ANZSBT Symposium: Red cells behaving badly! <i>Chairs: Alison Badger and Joanne Tan</i>	Meeting Room 212 & 213
1400	Normal and disordered human erythropoiesis	Mohan Narla
1430	Transfusions and troubles in patients with SCD	Mary Comande, Gemma Crighton & Anthea Greenway
1500	Iron refractory iron deficiency anemia: pathophysiology and management of a frequently missed iron disorder	Dorine Swinkels
1400 - 1530	THANZ Symposium: Platelet formation, function and therapy - novel insights (Kindly sponsored by Swedish Orphan Biovitrum (Sobi)) <i>Chairs: Vivien Chen and James McFadyen</i>	Meeting Room 219
1400	Novel platelet targeted therapeutics	Karlheinz Peter
1430	Novel mechanisms of thrombopoiesis	Elizabeth Gardiner
1500	Platelet genomics	Jorge Di Paola
1400 - 1530	Nurses Symposium: Familial haematology <i>Chairs: Daniela Klarica and Catherine Vassili</i>	Meeting Room 220
1400	Familial haematology	Lucy Fox
1445	The role of the genetic counsellor	Nicole Den Elzen
1530 - 1600	Afternoon Tea	Exhibition Hall
1600-1730	HSANZ Symposium: Acute Myeloid Leukemia (Kindly sponsored by AbbVie) <i>Chairs: Chyn Chua and Meaghan Wall</i>	Plenary 3
1600	Targeted therapies in AML	Eytan Stein
1630	Germline predisposition to malignancy	Lucy Godley
1700	The evolution of the genetic haematology service at Peter MacCallum Cancer Centre and Royal Melbourne Hospital	Lucy Fox
1600-1730	ANZSBT Symposium: Implementing change <i>Chairs: Amanda Catherwood and Philip Crispin</i>	Meeting Room 212 & 213
1600	Implementation of a new blood draw method	Gill Archer
1620	NIPT RHD for high-risk pregnancies	James Daly
1640	Introduction of RHD NIPT screening for RhD negative women	Anastazia Keegan
1700	Quality Use of Pathology Program (QUPP)	Kristen Brown and David Roxby

...continued overleaf

1600-1730	THANZ Symposium: Emerging technologies in thrombosis and haemostasis <i>Chairs: Danny Hsu and Grace Gilmore</i>	Meeting Room 219
1600	Mechanobiology inspired anti-thrombotic strategies and point-of-care microtechnologies	Arnold Ju
1630	Microfluidic applications in immunothrombosis	Freda Passam
1700	Using AI to decipher thrombocytopenia	Philip Choi
1600-1730	Nurses Symposium: Update on new therapies <i>Chairs: Hayley Beer and Jacqueline Jagger</i>	Meeting Room 220
1600	New therapies in myeloma	Hannah Kelly
1618	New therapies in lymphoma	Katharine Lewis
1636	New therapies in CLL	Emma Huybens
1654	New therapies in treating GVHD	Alex Rivalland
1600-1700	BMTSAA Symposium <i>Chair: Dominic Fernandez</i>	Meeting Room 211
1600	CD3 cell dose in autologous haematopoietic stem cell transplant as a predictor of engraftment and of overall survival in patients with myeloma/lymphoma	Emmanuel Charumbira
1615	A network approach to implementing a laboratory aseptic technique competency	Karieshma Kabani
1630	Poster presentations	
1730 - 1930	Welcome Reception (<i>Supported by BeiGene</i>)	Exhibition Hall



Monday 6 November

At a Glance

0830-1000	HSANZ Free Communications 1: Acute leukaemia Plenary 3 (Kindly sponsored by Jazz Pharmaceuticals) HSANZ Free Communications 2: Myeloma Meeting Room 211 HSANZ Free Communications 3: CLL / Basic science lymphoid malignancy Meeting Room 217 (Kindly sponsored by CSL) HSANZ Free Communications 4: DS/MPN/CML/ Bone marrow failure Meeting Room 218 (Kindly sponsored by Astellas Pharma)		ANZSBT Presidential Symposium Meeting Room 212 & 213	THANZ Free Communications 1 Meeting Room 219	Nurses and HSANZ: PROMS Meeting Room 220 (Kindly sponsored by BeiGene Australia)
1000-1030	Morning Tea Exhibition Hall				
1030-1200	HSANZ / THANZ Presidential Symposium Plenary 3		ANZSBT Symposium: Red cells behaving very badly! Meeting Room 212 & 213		Nurses Free Communications 1 Meeting Room 220
1200-1300	Lunch Exhibition Hall				
1200-1300	THANZ AGM Meeting Room 219				
1200-1300	Myeloma Special Practice Network Meeting Meeting Room 220				
1300-1400	Ruth Sanger Oration: Turning the page on blood typing: Reflections on a classic text Plenary 3 Prof Robert Flower				
1400-1530	HSANZ & THANZ Combined Symposium: Platelet biology and MPN management Plenary 3	HSANZ Symposium: Equity, diversity and inclusion Meeting Room 211	ANZSBT Symposium: Transfusion black magic Meeting Room 212 & 213		Nurses Symposium: Infections in haematological malignancies Meeting Room 220
1530-1600	Afternoon Tea Exhibition Hall				
1600-1730	HSANZ Symposium: CML Plenary 3		ANZSBT & THANZ Symposium: ICU and trauma Meeting Room 212 & 213		Nurses Symposium: Lead with more confidence, clarity and courage in 2024 Meeting Room 220
1730-1830	Poster Viewing Exhibition Hall				
1800-1900 (ticket required to attend - places limited)	HSANZ Masterclass 1: Managing primary refractory AML and bridging to transplant <i>Eytan Stein</i>				Meeting Room 211
	HSANZ Masterclass 2: T-cell NHL case studies <i>Kate Cwynarski</i>				Meeting Room 217
	ANZSBT Masterclass 1: Mechanistic insights in human hemolytic anemias <i>Mohan Narla</i>				Meeting Room 212 & 213
	ANZSBT Masterclass 2: Transfusion in solid organ transplant <i>Andrew Charlton</i>				Meeting Room 218
	THANZ Masterclass 1: Racial differences in thrombosis <i>Pantep Anchaisuksiri</i>				Meeting Room 219
	Nurses Masterclass: Leading sustainable practice change: Strategies to enable routine integration of ePROs into practice <i>Linda Watson</i>				Meeting Room 220

Monday 6 November

0830 - 1000	HSANZ Free Communications 1: Acute Leukaemia (Kindly sponsored by Jazz Pharmaceuticals) <i>Chairs: Christina Brown and Edward Chew</i>	Plenary 3
0830	Harnessing the stress response for immunity in acute myeloid leukaemia	Basit Salik
0845	Blinatumomab in combination with an intensive paediatric protocol results in high rates of end-consolidation MRD negativity – update of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "SUBLIME" Study	Matthew Greenwood
0900	High expression of DUX4 mRNA is a reliable indicator of DUX4-rearranged acute lymphoblastic leukaemia	Jacqueline Rehn
0915	STING agonists exert a direct anti-leukaemic effect in AML via induction of apoptosis	Yin Yuan
0930	Blinatumomab with Reduced Intensity Chemotherapy for Older Adults with Newly Diagnosed Ph negative B-Precursor Acute Lymphoblastic Leukemia – Final Results of the ALLG ALL08 Study	Shaun Fleming
0945	Novel clinicogenomic findings in the emerging entity of acute myeloid leukaemia with UBTF tandem duplications	Sean Harrop

0830 - 1000	HSANZ Free Communications 2: Myeloma <i>Chairs: Georgia McCaughan and Andrew Spencer</i>	Meeting Room 211
0830	Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma	Nicholas Bingham
0845	Predicting treatment outcome in multiple myeloma: The correlation with circulating tumour DNA-based molecular response and minimal residual disease	Sridurga Mithraprabhu
0900	Survival benefit of birtamimab in Mayo Stage IV AL amyloidosis in the Phase 3 VITAL clinical trial was consistent across all key baseline variables	Adam Cohen
0915	Optimisation of laser capture microdissection with tandem mass spectrometry for the diagnosis of amyloid subtype.	James Rowland
0930	An Australian Amyloidosis Network (AAN) analysis of Australian patients with AL amyloidosis treated with bortezomib-based chemotherapy	Anthea Gibbons
0945	The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine(PCAB) in relapsed and refractory multiple myeloma(RRMM) in the era of novel therapy, including as a bridge to CAR-T therapy	Eric Wenlong Li

...continued overleaf

0830 - 1000	HSANZ Free Communications 3: CLL / Basic Science Lymphoid Malignancy (Kindly sponsored by CSL) <i>Chairs: Mary Ann Anderson and Xavier Badoux</i>	Meeting Room 217
0830	Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study	Constantine Tam
0845	Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-year follow-up from the FD cohort of the phase 2 CAPTIVATE study	Constantine Tam
0900	Past informs the future: outcomes post allogeneic stem cell transplantation in chronic lymphocytic leukaemia (CLL)	Rory Bennett
0915	Time-limited venetoclax-rituximab is effective for patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon	Thomas Lew
0930	A novel analysis of histone methylation marks in CART cell clinical products and T cell substrates identifies new transcription factors and associations with product expansion	Salvatore Fiorenza
0945	Targeted next generation sequencing (NGS) of circulating tumour DNA (ctDNA) in patients with aggressive B-cell lymphoma - from diagnosis to transformation at relapse	Jake Shortt

0830 - 1000	HSANZ Free Communications 4: DS/MPN/CML/Bone marrow failure (Kindly sponsored by Astellas Pharma) <i>Chairs: Liesl Butler and Ben Carnley</i>	Meeting Room 218
0830	Dissecting immune dysregulation in acquired Bone Marrow Failure Syndromes to identify new therapeutic leads	Rachel Koldej
0845	Sensitive measurement of residual disease in granulocytes and T cells strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy	Ilaria Pagani
0900	Clonal haematopoiesis mutants detected at the time of stopping therapy are associated with achievement of treatment-free remission in patients with chronic myeloid leukaemia	Adelina Fernandes
0915	Real-World Outcomes of Elderly Patients with Myelodysplastic Syndromes/Low Blast Count Acute Myeloid Leukaemia Treated with Azacitidine: A Single Centre Retrospective Study	Tomas Mahaliyana
0930	Leukemic transformation STEMming from myeloproliferative neoplasm: Resolving the loss of stem cell heterogeneity	Julian Grabek
0945	Long road to a short diagnosis – detection of a novel germline TERT variant underlying a complex multisystem telomere biology disorder	Meena Nagrethinam

...continued overleaf

0830 - 1000	ANZSBT Presidential Symposium <i>Chairs: Philip Crispin and Anastazia Keegan</i>	Meeting Room 212 & 213
0830	Monitoring transfusion and patient safety risks	Penny O'Beid
0848	Characterisation of the Kidd blood group system in a Kenyan population	Rachel Githiomi
0906	Investigating biomarkers of bleeding in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass using proteomics	Suelyn van den Helm
0924	Massively Parallel Sequencing: the next generation non-invasive prenatal testing platform for alloimmunised pregnant women	Genghis Lopez
0942	Ultra-massive transfusion: Predictors of occurrence and in-hospital mortality from the Australian and New Zealand Massive Transfusion Registry	Marsali Maclean

0830 - 1000	THANZ Free Communications 1 <i>Chairs: Robert Andrews and Caroline Reddell</i>	Meeting Room 219
0830	GP1b-FilaminA interaction regulates megakaryocyte localization and budding during platelet biogenesis	Marc Ellis
0845	Matrix Metalloproteinases as a Potential Therapeutic Target to Reduce Joint Damage in Haemophilic Arthropathy	Wayne Hauw
0900	Investigating the role of platelet chemokines in the development of acute lung injury	Jemma Fenwick
0915	Endoplasmic reticulum (ER) stress activation determines megakaryocyte and platelet ER chaperone distribution.	Yvonne Kong
0930	Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENER8-1	Dominic Pepperell
0945	Fibrinolysis normalisation following cardiac bypass surgery: a prospective, observational study of recovery timeline and clinical associations.	Lucy Coupland

0830 - 1000	Nurses & HSANZ Symposium: PROMS <i>(Kindly sponsored by BeiGene Australia)</i> <i>Chairs: Hayley Beer and Lindsay Scudder</i>	Meeting Room 220
0830	Integrating electronic Patient Reported Outcomes (ePROs): Exploring the benefits to patients, clinical teams and the system	Linda Watson
0900	Using PROMS to assess transfusion outcomes in patients with myelodysplastic syndromes (MDS)	Allison Mo
0930	PROMS in allogeneic stem cell transplant survivorship	Nicole Loft
1000 - 1030	Morning Tea	Exhibition Hall

...continued overleaf

1030-1200	HSANZ / THANZ Presidential Symposium <i>Chairs: Steven Lane and Chee Wee Tan</i>	Plenary 3
1030	Local Anticoagulation via Gene Transfer: Towards Prevention of Cardioembolic Stroke	Megha Kadian
1045	MTH1 protects platelet mitochondria from oxidative damage and is essential for GPCR-dependent platelet function and thrombosis	Jianlin Qiao
1100	T-cell receptor sequencing confirms long-term in vivo persistence of adoptively transferred donor-derived pathogen and tumour antigen specific T-cells for myeloid malignancies in recipients of stem cell transplant (the INTACT trial)	Emily Blyth
1115	Genomic insights into primary refractory multiple myeloma: Exploring circulating cell-free tumour DNA analysis	Sridurga Mithraprabhu
1130	Tracking in vitro development of RUNX1+ haemogenic endothelium	Ritika Saxena
1145	Interim analysis of a nation-wide, investigator-initiated trial of glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP in patients ≤65 years of age with high-risk DLBCL: COALITION	Adrian Minson
1030-1200	ANZSBT Symposium: Red cells behaving very badly! <i>Chair: Melissa May and Tina Noutsos</i>	Meeting Room 212 & 213
1030	How to diagnose iron dyshomeostasis: Perspective of the clinical biochemistry lab	Dorine Swinkels
1100	Pathophysiology of Human Red Cell Membrane Disorders	Mohan Narla
1130	How I manage patients with red cell membrane (spectrin) disorders who need recurrent transfusions	Hasna Tokhi

...continued overleaf

1030-1200	Nurses Free Communications 1 <i>Chairs: Donna Gairns and Andrew Steele</i>	Meeting Room 220
1030	Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma compared to healthy controls: An exploratory study	Priscilla Gates
1040	The Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM) validated for clinical use.	Tracy King
1100	Objective measures of sleep disturbances in patients receiving steroids for the treatment of multiple myeloma: Findings from a pilot study.	Tracy King
1115	Nurse Practitioner blood product prescribing in malignant haematology and bone marrow transplantation, a single centre experience	Catherine Vassili
1130	Strengthening communication, education and support for consumers of allogeneic stem cell transplant by experiences of care surveys	Nicole Loft
1145	Developing a national support and information program for younger people living with myeloma in Australia	Laura Wells
1200-1300	Lunch	Exhibition Hall
1200-1300	Myeloma Special Practice Network Meeting	Meeting Room 220
1200-1300	THANZ AGM	Meeting Room 219
1300-1400	Ruth Sanger Oration <i>Chair: Anastazia Keegan</i>	Plenary 3
1300	Turning the page on blood typing: Reflections on a classic text	Robert Flower
1400-1530	HSANZ / THANZ Combined Symposium: Platelet biology and MPN management <i>Chairs: Christopher Ward and Paul Yeh</i>	Plenary 3
1400	Platelet function and MPNs	Jorge Di Paola
1430	Sequencing and MPNs	Andrew Perkins
1500	ET - challenges in current management	Claire Harrison
1400-1530	HSANZ Symposium: Equity, Diversity and Inclusion <i>Chair: Peng Lee</i>	Meeting Room 211
1400	Te Mana o te Awa – weaving equity into healthcare	Ellyn Proffit and Pania Ranga
1445	Spiritual connection to Country, family, and life through blood: Aboriginal and Torres Strait Islander perspectives on culturally safe healthcare	Tina Noutsos and Maree Perry

...continued overleaf

1400-1530	ANZSBT Symposium: Transfusion black magic <i>Chair: Allison Mo</i>	Meeting Room 212 & 213
1400	NBTC FFP audit at Blood	Lisa Clarke
1430	Granulocytes infusions: NZ experience	Richard Charlewood
1500	Controversies and new things in the immunohaematology of transplantation	Chris Hogan

1400 - 1530	Nurses Symposium: Infections in haematological malignancies <i>Chairs: Lacey Strachan and Katrina Wragg</i>	Meeting Room 220
1400	Infections in CAR-T	Ty Simpson
1430	Nurse-led antibiotic delabelling	Belinda Lambros
1500	Advising patients on a healthy microbiome - less is more	Olivia Smibert

1530-1600	Afternoon tea	Exhibition Hall
------------------	----------------------	------------------------

1600-1730	HSANZ Symposium: CML <i>Chair: Deborah White</i>	Plenary 3
1600	Update on treatment options in CML	Michael Mauro (supported by Novartis)
1630	Genetics of CML	David Yeung
1700	Myeloproliferative neoplasms in pregnancy	Cecily Forsyth

1600-1730	ANZSBT & THANZ Symposium: ICU and trauma <i>Chair: Anastazia Keegan</i>	Meeting Room 212 & 213
1600	Transfusion therapy for shocked trauma patients	Biswadev Mitra
1630	ECMO and anticoagulation	James Winearls
1700	Fibrinolysis and trauma	Nicola Mutch

1600-1730	Nurses Symposium: Lead with more confidence, clarity and courage in 2024 <i>Chair: Yvonne Panek-Hudson</i>	Meeting Room 220
1600	Lead with more confidence, clarity and courage in 2024	Annree Wogan
1700	Panel discussion	Panelists: Linda Watson, Annree Wogan, Mitchel Lincoln, Hayley Beer

...continued overleaf

1730-1830	Poster Viewing	Exhibition Hall
1800-1900	HSANZ Masterclass	Meeting Room 211
1800	Managing primary refractory AML and bridging to transplant	Eytan Stein
1800-1900	HSANZ Masterclass	Meeting Room 217
1800	T-cell NHL case studies	Kate Cwynarski
1800-1900	ANZSBT Masterclass	Meeting Room 212 & 213
1800	Mechanistic insights in human hemolytic anemias	Mohan Narla
1800-1900	ANZSBT Masterclass	Meeting Room 218
1800	Transfusion in solid organ transplant	Andrew Charlton
1800-1900	THANZ Masterclass <i>Chair: Chee Wee Tan</i>	Meeting Room 219
1800	Racial differences in thrombosis	Pantep Angchaisuksiri
1800-1900	Nurses Masterclass	Meeting Room 220
1800	Leading sustainable practice change: Strategies to enable routine integration of ePROs into practice	Linda Watson

Please note: Masterclasses are not included in the full registration and are an additional cost. Please see the Registration Desk if you would like to attend.



Tuesday 7 November

At a Glance

0830-1000	<p>HSANZ Free Communications 5: Aggressive lymphoma Plenary 3 (Kindly sponsored by Roche Products Limited)</p> <p>HSANZ Free Communications 6: Low-grade lymphoma Meeting Room 218</p>	<p>ANZSBT Free Communications: Clinical Meeting Room 212 & 213</p> <p>ANZSBT Free Communications: Transfusion professionals Meeting Room 216</p> <p>ANZSBT Free Communications: Laboratory / Scientific Meeting Room 217</p>	<p>THANZ Free Communications 2 Meeting Room 219 (Kindly sponsored by Novo Nordisk)</p>	<p>Nurses Symposium: Working towards equity Meeting Room 220</p>
1000-1030	Morning Tea Exhibition Hall			
1030-1200	<p>HSANZ Free Communications 7: Albert Baikie Memorial Medal Plenary 3</p> <p>HSANZ Free Communications 8: BMT / Cellular therapies Meeting Room 216</p> <p>HSANZ Free Communications 9: Supportive care/Infectious disease/Non-malignant Meeting Room 217</p>	<p>ANZSBT Symposium: Immune impacts of transfusion Meeting Room 212 & 213</p>	<p>THANZ Symposium: Bleeding disorders in 2023 and beyond Meeting Room 219</p>	<p>Nurses Free Communications 2 Meeting Room 220</p>
1200-1300	Lunch Exhibition Hall			
1200-1300	HSANZ AGM Meeting Room 218			
1200-1300	Apheresis Special Practice Network Meeting Meeting Room 220			
1300-1400	Carl de Gruchy Oration: Haematology: What a difference we can make! Plenary 3 Prof Andrew Roberts			
1400-1530	<p>HSANZ Symposium: Lymphoma Plenary 3 (Kindly sponsored by Gilead Sciences)</p>	<p>QA-Laboratory Haematology Meeting Room 216</p>	<p>ANZSBT & HSANZ Combined: HOW collaborative Meeting Room 212 & 213</p>	<p>THANZ Free Communications 3 Meeting Room 219</p> <p>Nurses Symposium: Apheresis Meeting Room 220</p>
1530-1600	Afternoon Tea Exhibition Hall			
1600-1700	<p>HSANZ Symposium: CLL Plenary 3</p>	<p>ANZSBT Symposium: Is it all worth it? Meeting Room 212 & 213</p>	<p>THANZ Symposium: Venous thrombosis and fibrinolysis - basic mechanisms and therapeutic opportunities Meeting Room 219</p>	<p>Nurses Symposium: New models in supportive care & Nurses Awards Presentation Meeting Room 220</p>
1730-1800 (ticket required to attend - places limited)	HSANZ Masterclass 3: Treatment of transformed CLL Jennifer Brown (supported by AstraZeneca)			Meeting Room 214
	HSANZ Masterclass 4: Sequencing of CART versus Adam Cohen (supported by Janssen)			Meeting Room 216
	ANZSBT Masterclass 3: Body iron distribution parameters in the diagnosis of iron toxicity in primary and secondary forms of iron overload Dorine Swinkels			Meeting Room 217
	ANZSBT Masterclass 4: Initiatives to minimise wastage of blood products Gill Archer			Meeting Room 218
	THANZ Masterclass 2: Management of ITP Robert Bird			Meeting Room 219
1900-2345	Gala Dinner & Awards Melbourne Room			

Tuesday 7 November

0830 - 1000	HSANZ Free Communications 5: Aggressive lymphoma (Kindly sponsored by Roche Products Limited) <i>Chairs: Allison Barraclough and Bill Renwick</i>	Plenary 3
0830	Improvement in CAR-T outcomes over time – lessons from the UK experience	Stephen Boyle
0845	Single-institution outcomes of standard-of-care chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in third-line or beyond: an Australian real-world experience	Mark Dowling
0900	Real-world outcomes of patients with double-hit lymphoma treated from 2013 to 2023 at Royal Melbourne Hospital and Peter MacCallum Cancer Centre	Victor Lin
0915	Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma	Michael Dickinson
0930	Glofitamab monotherapy in patients with relapsed/refractory Large B-Cell Lymphoma: Extended follow-up and landmark analyses from pivotal phase II study	Michael Dickinson
0945	Epcoritamab SC induces durable complete remissions in patients with relapsed/refractory diffuse large B-cell lymphoma: long-term results of EPCORE NHL 1	Robin Gasiorowski

0830 - 1000	HSANZ Free Communications 6: Low-grade lymphoma <i>Chairs: Matthew Ku and Teresa Leung</i>	Meeting Room 218
0830	Interim 3D volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary CNS lymphoma (PCNSL)	Arina Martynchyk
0845	T cell CD62L expression following nivolumab therapy is associated with long term response to rituximab-nivolumab in treatment naive follicular lymphoma: results from the 1st FLOR study	Rachel Koldej
0900	Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial	Stephen Opat
0915	Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia	Dipti Talaulikar
0930	A multicentre comparative audit of Hodgkin Lymphoma patients receiving ABVD chemotherapy with or without routine GCSF prophylaxis	Bernadette De Zylva
0945	A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data	Emma Verner

...continued overleaf

0830 - 1000	ANZSBT Free Communications: Clinical <i>Chairs: Amanda Ormerod and Philip Crispin</i>	Meeting Room 212 & 213
0830	Economic evaluation of prophylactic immunoglobulin versus prophylactic antibiotics in haematological malignancies: preliminary results from the RATIONAL feasibility trial	Sara Carrillo De Albornoz
0845	Understanding transfusion practices and comorbidities in hospitalised elderly patients	David Roxby
0900	ABO-mismatched platelet transfusions, immune platelet refractoriness, and platelet support	Min-Hi Han
0915	Storage of platelets for transfusion influences cross-talk with malignant HepG2 cells	Thomas Hueneburg
0930	Evaluating the quality of X-ray irradiated deglycerolised red cells stored in SAGM	Kelly Winter
0945	Ultrarapid Iron Polymaltose infusions are safe for management of iron deficiency	Iouri Banakh

0830 - 1000	ANZSBT Free Communications: Transfusion professionals <i>Chairs: Rebecca McLean and Chris Akers</i>	Meeting Room 216
0830	Management of moderate/severe iron deficiency anaemia in stable patients presenting to the Emergency Department: A retrospective audit	Allison Mo
0845	Drugs in blood: Is it safe to co-administer medications and red cell transfusions?	Richard Charlewood
0900	Beyond the surface: a tertiary centre investigation of transfusion reaction incidence and type	Kaitlyn Wiltshire and Ruby Garland
0915	Patient Blood Management Practices in paediatric patients undergoing craniostomy surgery.	Malaika Perchard
0930	Development of a suite of state-wide tools to support safe transfusion practice with the introduction of an Electronic Medical Record	Amanda Catherwood
0945	O RhD negative red cell transfusions in small regional South Australian hospitals	Cathie Gore

...continued overleaf

0830 - 1000	ANZSBT Free Communications: Laboratory/Scientific <i>Chair: Allison Badger</i>	Meeting Room 217
0830	Whole blood for trauma resuscitation: Is it pro-inflammatory?	Joanne Tan
0848	Japanese Encephalitis Virus Antibody Seroprevalence Among Blood Donors Following an Outbreak of Infections in Southern and Eastern Parts of Australia	Rena Hirani
0906	Characterisation of caspase activation in fresh, cryopreserved, and apoptotic platelets	Lauren Waters
0924	The impact of JK-null variants on red blood cell biology	Rebecca Griffiths
0942	Impact of Newly Emerging Dengue Outbreak on Blood Supply at a Hospital-based Blood Bank in Oman	Arwa AL-Riyami
0830 - 1000	THANZ Free Communication 2 <i>(Kindly sponsored by Novo Nordisk)</i> <i>Chairs: Joanne Joseph and Gabrielle Pennings</i>	Meeting Room 219
0830	Outcomes of FXa-inhibitor associated gastrointestinal bleeding: Do prohaemostatic agents change anything?	Sara Ng
0845	Spontaneous bleeding in chronic kidney disease patients - global coagulation assays may be predictive of bleeding risk	Rowena Brook
0900	Endothelial-Targeted CD39 Ameliorates Acute Endothelial Toxin-Induced Pulmonary Hypertension in a Murine Model	Abbey Willcox
0915	Patients with COVID-19 exhibit diminished thrombomodulin mediated inhibition of endogenous thrombin potential	Alison Slocombe
0930	The efficacy of prohaemostatic agents in the management of FXa-inhibitor-related intracranial haemorrhages	Sara Ng
0945	Incidence of venous thromboembolism in patients with major burns receiving standard dose thromboprophylaxis: a retrospective study	Hadley Bortz
0830 - 1000	Nurses Symposium: Working towards equity <i>Chair: Trish Joyce</i>	Meeting Room 220
0830	Overcoming ageism	Michael Krasovitsky
0900	Working towards equity in the care of Aboriginal and Torres Strait Islander people with cancer	Andrea Casey
0930	LGBTQI inclusive cancer care	Rosalie Power
1000 - 1030	Morning Tea	Exhibition Hall

...continued overleaf

1030-1200	HSANZ Free Communications 7: Albert Baikie Memorial Medal Session <i>Chairs: Christina Brown and Peng Lee</i>	Plenary 3
1030	Interventions and therapy at end of life in haematological malignancy: A retrospective cohort study on healthcare utilisation and palliative care use	Briony Shaw
1045	Clonal and transcriptional determinants of post-CAR T cell relapse in B-cell acute lymphoblastic leukaemia	James Kuzich
1100	Molecular MRD assessment is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy	Jad Othman
1115	Multiple myeloma-derived circulating extracellular vesicles affect normal human stromal cell behaviour and promote tumor progression: a multi-omic approach	Annie Reale
1130	Next generation sequencing RNA Fusion Panel for the diagnosis of haematological malignancies – an Australian first.	Trung Ngo
1145	Tisagenlecleucel for relapsed/refractory high grade B cell lymphoma: a single centre Australian experience	Rebecca Wayte

1030-1200	HSANZ Free Communications 8: BMT / Cellular therapies <i>Chairs: Lynette Chee and David Curtis</i>	Meeting Room 216
1030	Total body irradiation-based myeloablative T-cell-replete haploidentical stem cell transplantation: A single institution experience	Sarah Tan
1045	The addition of ATG to reduced-intensity conditioning transplantation from a matched unrelated donor results in similar GRFS but increased TRM when compared to T cell replete matched sibling donor transplantation	Ray Mun Koo
1100	Quantifying treatment burden of cytomegalovirus reactivation following allogeneic haematopoietic stem cell transplantation.	Nirija Ranjit Anderson
1115	Use of haplo-identical donor stem cells increase the risk of CMV reactivation in patients receiving post-transplant cyclophosphamide for GVHD prophylaxis	James Schwarzer
1130	Allogeneic stem cell transplantation achieves long-term remissions in patients with mantle cell lymphoma, including TP53-mutated disease	Thomas Lew
1145	Allogeneic haematopoietic stem cell transplant patients in the intensive care unit – a ten year retrospective cohort study	Christopher Heydon

...continued overleaf

1030-1200	HSANZ Free Communications 9: Supportive care/ Infectious disease/Non-malignant <i>Chair: Kylie Mason and Annette Neylon</i>	Meeting Room 217
1030	Intensive Pegcetacoplan Dosing in the Management of Acute Haemolysis as Part of the 307 Open-Label Extension Study	Jeff Szer
1045	Characteristics of paediatric and adult patients with atypical haemolytic uraemic syndrome (aHUS) treated with eculizumab – an Australian clinical audit.	Danny Hsu
1100	Tmprss6 siRNA treatment in mice stops hepcidin reduction across pregnancy	Katherine Fielding
1115	Genotype to phenotype: what are those dots?	Malaika Perchard
1130	A novel telemedicine therapeutic intervention to improve the health of post-transplant patients in their home	David Ma
1145	Outcomes of patients with haematological malignancy admitted to ICU and factors associated with survival: a retrospective cohort study	Briony Shaw

1030-1200	ANZSBT Symposium: Immune impacts of transfusion <i>Chairs: Liz Lennox and Joanne Tan</i>	Meeting Room 212 & 213
1030	Transfusion associated graft versus disease	Philip Crispin
1100	New insights into the pathogenesis and prevention of TRALI	John-Paul Tung
1130	Immune function of cold-stored platelets	Ben Winskel-Wood

1030-1200	THANZ Symposium: Bleeding disorders in 2023 and beyond <i>Chairs: Liane Khoo and Huyen Tran</i>	Meeting Room 219
1030	vWD genomics	Jorge Di Paola
1100	Management of vWD	Amanda Davis
1130	Haemophilia gene therapy	Chee Wee Tan

...continued overleaf

1030-1200	Nurses Free Communications 2 <i>Chairs: Nicole Loft and Gemma White</i>	Meeting Room 220
1030	A scoping review of CD20-CD3 bispecific antibody adverse events to inform nursing practice in B-cell non-Hodgkin Lymphoma	Sam van der Linde
1048	Don't think twice, do an ICE...score.	Madeline McKeague
1106	Transforming Survivorship Care: Patient informed follow up care after Allogeneic Stem Cell Transplantation	Bianca Cirone
1124	Creation and implementation of a Haematopoietic Progenitor Cell (HPC) infusion policy, educational resources and competency assessment for nurses	Kirsten Bubner
1142	Implementation of a new extracorporeal photopheresis (ECP) service at the Royal Brisbane & Women's Hospital	Kari Mudie
1200-1300	Lunch	Exhibition Hall
1200-1300	HSANZ AGM	Meeting Room 218
1200-1300	Apheresis Special Practice Network meeting	Meeting Room 220
1300-1400	Carl de Gruchy Oration <i>Chair: Steven Lane</i>	Plenary 3
1300	Haematology: What a difference we can make!	Andrew Roberts
1400-1530	HSANZ Symposium: Lymphoma <i>(Kindly sponsored by Gilead Sciences)</i> <i>Chairs: Gareth Gregory and Sumita Ratnasingam</i>	Plenary 3
1400	CNS lymphoma	Kate Cwynarski
1430	Immunotherapy for B-cell lymphoma	Chan Cheah
1500	Molecular biomarkers in lymphoid neoplasms	Paul Yeh
1400-1530	ANZSBT & HSANZ Combined: HOW collaborative <i>Chair: Lisa Clarke</i>	Meeting Room 212 & 213
1400	Management of haematological malignancies in pregnancy	Giselle Kidson-Gerber
1430	Fertility and haematological malignancies	Kate Stern
1500	Interesting cases of intrauterine transfusion	Anastazia Keegan

...continued overleaf

1400-1530	THANZ Free Communications 3 <i>Chairs: Natalie Pecheniuk and Stephanie P'Ng</i>	Meeting Room 219
1400	Case-control study on dynamic upper limb ultrasound and biomarkers in idiopathic upper extremity deep vein thrombosis	Hiu Lam Agnes Yuen
1415	Oral anticoagulant use in Australian atrial fibrillation patients with low risk of stroke: a national cohort study	Adane Kefale
1430	Perioperative management with efanesoctocog alfa in patients with hemophilia A in the phase 3 XTEND-1 study	Liane Khoo
1445	Investigating the bidirectional interactions between platelets and colorectal cancer and the effects of aspirin	David Capraro
1500	Activated Coagulation Factor XII (Factor XIIa): A unique target for in vivo molecular imaging	Aidan Walsh
1400-1530	Nurses Symposium: Apheresis <i>Chairs: Jenny Hempton and Andrew Steele</i>	Meeting Room 220
1400	cGVHD patients treated with ECP	Kari Mudie
1430	Collection efficiency in CAR-T collection	Paul Malau
1500	Case study: Glycosorb-ABOi secondary plasma device procedure	Romony Jeans
1400-1530	QA-Laboratory Haematology <i>Chairs: John Giannoutsos and Surender Juneja</i>	Meeting Room 216
1400	QAP-Morphology	John Giannoutsos
1430	Applications of digital morphology in haematology	Jessica Elliott and Surender Juneja
1500	Flow cytometric monitoring of lymphoid malignancies following antigen-directed immunotherapies	Kah Lok Chan
1530-1600	Afternoon Tea	Exhibition Hall
1600-1700	HSANZ Symposium: CLL <i>Chair: Mary Ann Anderson</i>	Plenary 3
1600	Time-limited vs ongoing therapy for CLL	Jennifer Brown (supported by AstraZeneca)
1620	Update on treatment of Richter Syndrome	Philip Thompson
1640	Treatment resistance in CLL	Xavier Badoux

...continued overleaf

1600-1700	ANZSBT Symposium: Is it all worth it? <i>Chair: Amanda Ormerod</i>	Meeting Room 212 & 213
1600	Transfusion in haem-onc – current challenges	Andrew Charlton
1630	Does transfusion improve QoL in patients with MDS?	Allison Mo
1600-1700	THANZ Symposium: Venous thrombosis and fibrinolysis - basic mechanisms and therapeutic opportunities <i>Chairs: Ashwini Bennett and Robert Medcalf</i>	Meeting Room 219
1600	Cellular regulation of fibrinolysis	Nicola Mutch
1620	Thrombolysis and pulmonary embolism	Ross Baker
1640	Fibrinolysis and plasminogen activation in thrombolysis and potential outcomes	Cherry Keragala
1600-1700	Nurses Symposium: New models in supportive care <i>Chairs: Priscilla Gates and Lindsay Scudder</i>	Meeting Room 220
1600	Prehabilitation to improve outcomes after Autologous stem cell transplantation (PIRATE): A pilot randomised controlled trial protocol	Amy Dennett
1620	Care Plus – a study exploring early intervention with palliative care	Kylee Bellingham
1640	Awards presentation	Lindsay Scudder
1730 - 1830	HSANZ Masterclass <i>Chair: Philip Thompson</i>	Meeting Room 214
1730	Treatment of transformed CLL	Jennifer Brown (supported by AstraZeneca)
1730 - 1830	HSANZ Masterclass <i>Chair: Andrew Spencer</i>	Meeting Room 216
1730	Sequencing of CART versus	Adam Cohen (supported by Janssen)
1730 - 1830	ANZSBT Masterclass	Meeting Room 217
1730	Body iron distribution parameters in the diagnosis of iron toxicity in primary and secondary forms of iron overload	Dorine Swinkels
1730 - 1830	ANZSBT Masterclass	Meeting Room 218
1730	Initiatives to minimise wastage of blood products	Gill Archer
1730 - 1830	THANZ Masterclass: <i>Chair: Cherry Keragala</i>	Meeting Room 219
1730	Management of ITP	Robert Bird
1900-2345	Gala Dinner & Awards	Melbourne Room

Wednesday 8 November

At a Glance

0900-1030	HSANZ Symposium: Myeloma Plenary 3 (Kindly sponsored by Amgen)	ANZSBT Symposium: Transfusion practitioners Meeting Room 212 & 213	THANZ Symposium: Anticoagulation in special populations Meeting Room 219
1030-1100	Morning Tea Exhibition Hall		
1100-1245	Closing Symposium: Blood 2023 Plenary 3		



Wednesday 8 November

0900 - 1030	HSANZ Symposium: Myeloma (Kindly sponsored by Amgen) <i>Chairs: Joy Ho and Anna Kalff</i>	Plenary 3
0900	Sequencing therapies for relapsed myeloma in the Australian setting	Georgia McCaughan
0930	MRD monitoring in myeloma	Christian Bryant
1000	Amyloidosis	Simon Gibbs

0900 - 1030	ANZSBT Symposium: Transfusion practitioners <i>Chairs: Amanda Catherwood and Rebecca McLean</i>	Meeting Room 212 & 213
0900	EMR update - where are we now?	Penny O'Beid
0920	Haemovigilance - Lessons learned from STIR	Christine Akers
0940	Changing to one national health service	Gill Archer
1000	Check twice, label once!	SoYoung Choi-Maxwell

0900 - 1030	THANZ Symposium: Anticoagulation in special populations <i>Chairs: Hadley Bortz and Nicola Eaddy</i>	Meeting Room 219
0900	Anticoagulation and renal failure	Sunil Badve
0930	Anticoagulation and extremes of body weight	Jennifer Curnow
1000	Idiopathic upper extremity deep vein thrombosis	Agnes Yuen

1030 - 1100	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1100-1245	Closing Symposium: Blood 2033 <i>Chairs: Meaghan Wall, Amanda Ormerod, James McFadyen</i>	Plenary 3
1100	Exploring venous thromboembolism through 'omics' and big data: Insights and applications	Hannah Stevens
1130	How will we be managing inherited cancer predisposition syndromes in 10 years time?	Lucy Godley
1200	Transfusion 2024 (+10) – How will we be thinking about transfusion in the 2030s?	Andrew Charlton
1230	Closing	

International Speakers

HSANZ



Jennifer Brown


Supported by  AstraZeneca

Director, CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, USA



Claire Harrison

Deputy Medical Director, Guy's and St Thomas Hospital, UK



Adam Cohen

Supported by  Janssen Oncology

Director of Myeloma Immunotherapy, Amyloidosis Program, Abramson Cancer Center, University of Pennsylvania, USA



Michael J. Mauro

Supported by  NOVARTIS

Leader, Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, USA



Kate Cwynarski

Haem-Oncologist, University College London Hospital, UK



Eytan Stein

Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, USA



Lucy Godley

Clinical Director of Cancer Genetics, University of Chicago Medicine USA

ANZSBT




Gill Archer

Coordinator of PBM Service, Te Whatu Ora Health, NZ



Mohandas Narla

Distinguished Scientist Head, Laboratory of Red Cell Physiology, New York Blood Centre, USA



Andrew Charlton

Consultant Haematologist, NHS Blood and Transplant and Newcastle Hospitals, UK



Dorine Swinkels

Professor in Experimental Clinical Chemistry, Radboud University Medical Centre, The Netherlands

THANZ



Pantep Angchaisuksiri

Chief, Hemostasis and Thrombosis Unit, Ramathibodi Hospital, Thailand



Nicola Mutch

Personal Chair, University of Aberdeen, Scotland



Jorge Di Paola

Tenured Professor of Pediatrics and Division Chief, Pediatric Hematology Oncology, Washington University School of Medicine, USA

Nursing



Linda Watson

Oncology Nurse and Adjunct Professor, University of Calgary, Canada

Orators



Barry Firkin Orator

Shaun Jackson

Director of Cardiovascular Research, Heart Research Institute



Ruth Sanger Orator

Robert Flower

National Leader R&D, Australian Red Cross Lifeblood



Carl de Gruchy Orator

Andrew Roberts

Metcalf Chair of Leukaemia Research, Royal Melbourne Hospital / Peter MacCallum Cancer Centre / Walter and Eliza Hall Institute

General Information

Registration Desk

The desk is located on the exhibition concourse, opposite door 7 and open at the following time:

Sunday 5 November	0730-1800hrs
Monday 6 November	0730-1800hrs
Tuesday 7 November	0730-1800hrs
Wednesday 8 November	0800-1300hrs

Wi-Fi Code

Network: BLOOD2023

Password: Melbourne

Parents Rooms


Located on the ground floor of the convention centre and exhibition centre and indicated by an "A" on the venue map on page 1. Parent rooms offer a comfortable and private space for parents and children and feature everything you need to change or feed in privacy and comfort.

If you require assistance locating a parenting room while at the venue, please visit any customer service desk or ask one of our friendly team members.

Notes

Save the Date...

Blood 2024



27 – 30 October 2024

Brisbane Convention and
Exhibition Centre



The combined Annual Scientific Meeting of the:



HSANZ
Haematology Society of
Australia and New Zealand



Australian & New Zealand
Society of Blood Transfusion Ltd



THANZ
Thrombosis & Haemostasis society
of Australia and New Zealand